- Malignant lymphomas
- Leukemias
- Retinoblastoma
- Carcinoma of breast
- Ovarian cancer
- Mycosis fungoides
- Minimal Change Nephrotic Syndrome in Pediatric Patients
CTX GLS 200MG
| MRP | : |
|
| Price | : | ₹25.00 |
| You Save | : | ₹11.00 (30.56%) |
1 Vial(s)
CTX GLS 200mg Injection is a chemotherapy medication that contains cyclophosphamide as its active ingredient. It is utilized for the treatment of various malignancies, which refer to the abnormal growth of cells known as cancer, particularly when these cells spread to other organs. CTX GLS 200mg Injection is effective against malignant lymphomas, which are cancers originating from the body’s lymphatic system, including Hodgkin’s disease, lymphocytic lymphoma, and mixed-cell type lymphoma.
Additionally, it is indicated for the treatment of leukemias, neuroblastoma, ovarian cancer, retinoblastoma, and breast carcinoma. This injection can also be used to manage Minimal Change Nephrotic syndrome in children, a kidney condition characterized by significant protein loss in urine. However, CTX GLS 200mg Injection is contraindicated for use during pregnancy and in patients with acute infections, urinary tract infections, urinary outflow obstruction, and bone marrow disorders.
The administration of this medication may result in immune suppression, bone marrow failure, cardiotoxicity, renal toxicity, pulmonary toxicity, and the development of secondary malignancies. It is important to inform your healthcare provider if you have any pre-existing kidney disease, immune system disorders, cardiac issues, or liver conditions.
